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With the completion of the human genome project, it has 
become obvious that protein-coding genes comprise only 
2% of the genome, although the majority of the genome is 
transcribed into RNA. RNA molecules that lack protein-
coding potential are collectively referred to as non-coding 
(nc) RNAs. In addition to the well-known housekeeping 
rRNAs, tRNAs and small nuclear RNAs (snRNAs), the 
most intensively studied subgroup of ncRNAs are the 
microRNAs (miRNAs), which are well characterized by 
their size and uniform function. Another distinct class of 
ncRNAs, long ncRNAs (lncRNAs), are larger than 200 
nucleotides. They are markedly heterogeneous in size and 
cellular function. While the number of annotated lncRNA 
genes in the human genome outnumbers protein-coding 
genes (1), studies of their functional roles and detailed 
mechanisms account for less than 0.1% of all predicted 
lncRNAs (2).
Lung cancer is the most common cancer diagnosed 
worldwide. Despite surgical treatment and the development 
of more effective chemotherapeutics, lung cancer and its 
metastases are still the leading cause of cancer death in 
developed countries (3). Efforts to understand differences in 
patients’ responses have led to a focus on gene-expression 
differences. While initially the role of protein-coding 
genes and their mutations were studied to understand 
individual differences in lung cancer formation and to 
identify novel therapeutic targets (3), the focus in the last 
decade has shifted to ncRNAs (4,5). In various human 
cancers—including lung cancer—down-regulation of 
tumor suppressive miRNAs and up-regulation of oncogenic 
miRNAs have been described. Lung-cancer-associated 
miRNAs have the ability to regulate tumorigenesis, survival, 
angiogenesis, and migration and invasion of tumors (6); 
moreover, clinical studies have been carried out to correlate 
dysregulated expression of particular miRNAs with 
tumor responsiveness to chemotherapies (5). Similarly to 
microRNAs, lncRNAs were shown to play a fundamental 
role in cancer-cell growth, proliferation, cell death, invasion 
and metastasis formation (4); however, the majority of these 
genes are not yet functionally characterized. Currently, 
many attempts are focusing on the use of lncRNAs as 
prognostic markers in cancer patients, as tumor cells can be 
characterized by their distinct lncRNA profile (7).
In a recent paper, Seiler et al. used a siRNA screen to 
characterize 638 lung-cancer associated lncRNAs (8). Based 
on the siRNA screen, they selected a yet uncharacterized 
intergenic lncRNA (ENST00000567151) for further 
characterization. This lncRNA is overexpressed in primary 
lung adenocarcinoma and the authors referred to it as 
viability enhancing in lung cancer transcript (VELUCT). 
VELUCT expression was low (0.01 copies/cell) in the 
lung-cancer cell line NCI-H460, and the transcript was 
predominantly expressed in the chromatin fraction, 
exhibiting a half-life of 20–30 minutes.
The low abundance of VELUCT raised the question 
of whether it was functional or just transcriptional 
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noise. To support the functionality of this transcript, the 
authors studied the knock-out phenotype. Despite its low 
abundance, silencing with antisense oligos (ASOs) for 
VELUCT resulted in a loss of viability of several lung-
cancer cell lines. These results demonstrated that even an 
extremely low abundant lncRNA can have an important 
function at the cellular level.
Numerous lncRNAs have been shown to affect cell 
viability; however, the expression of these transcripts 
is typically much higher than VELUCT. One of the 
earliest identified lncRNAs, MALAT-1, is overexpressed 
in metastasizing lung adenocarcinoma and is associated 
with a high risk of developing metastasis (9). MALAT-1 
has since been shown to be upregulated and crucial for 
cell viability and proliferation in several cancer cell types 
(10-12). Recently, several other tumor-associated lncRNAs 
were shown to affect cell viability. The expression of 
DB327252 in lung tumors is upregulated compared to 
adjacent normal tissue, exhibiting a magnitude of expression 
similar to VELUCT, and silencing this transcript inhibited 
the proliferation of tumor cells (13). In small-cell lung 
cancer, the taurine up-regulated gene 1 (TUG1) lncRNA 
was found to be overexpressed, and knockdown of this 
gene inhibited proliferation, invasion and metastasis 
formation (14). Ectopic overexpression of the prostate-
cancer-specif ic PCGEM1 lncRNA contributed to 
cell proliferation (15). In contrast to the sequences 
mentioned above, some lncRNAs have been shown to be 
downregulated in cancer tissues. In non-small-cell lung 
carcinoma, the anti-sense transcript of the tumor suppressor 
in lung cancer 1 (TSLC1) RP11-713B9.1 was shown to 
be downregulated, and its functions as tumor suppressor 
were identified by its ability to decrease cell viability and 
proliferative signaling when overexpressed (16).
Currently ncRNA biology faces two challenges: 
the validation of lncRNAs identified by large-scale 
gene expression studies and the confirmation of their 
functionality in health and in disease. There is still a debate 
whether low-abundance lncRNAs are functional or just 
transcriptional noise that is rapidly removed by cellular 
quality control mechanisms (17). Although various criteria, 
including expression levels, splicing variants and sequence 
conservation, has been proposed to differentiate between 
functional and non-functional lncRNAs, a consensus has 
not yet been achieved. Even if a fraction of non-coding 
transcripts are non-functional and originate from aberrant 
transcription, thousands might have functions within cells, 
and an enormous effort is still needed to determine their 
specific functions. This effort is made more difficult by the 
low-level expression seen for most lncRNAs (1) and high 
inter-individual differences in lncRNA expression (18). 
Seiler et al. present one of the first examples of functionality 
of a low-abundance lncRNA, demonstrating the importance 
of lncRNAs in small amounts. In addition to individual 
characterization of lncRNAs, siRNA screening can be a 
powerful tool to study the functionality of hundreds of 
lncRNAs simultaneously to find potential new players in 
various cellular processes, as demonstrated by Seiler et al.
lncRNA biology is an emerging topic as evidenced by 
a 20-fold increase in the number of publications in the 
last decade (results of a PubMed search with the keyword 
“lncRNA”). The initial knowledge about a few differentially 
expressed transcripts has expanded into the functional 
characterization of over 100 lncRNA species; however, it 
seems our current knowledge is only the tip of the iceberg. 
In the future, innovative studies using novel methods—
even in the cases where the detection of a transcript first 
seems dubious—will bring us a deeper understanding of 
cellular functions and eventually lead to a more complex 
understanding of disease pathogenesis, possibly providing 
novel biomarkers and therapeutic targets.
Acknowledgements
Funding: This work was supported by the National 
R e s e a r c h  D e v e l o p m e n t  a n d  I n n o v a t i o n  O f f i c e 
(GINOP-2.3.2-15-2016-00015). J Danis is supported by 
the NTP-NFTÖ-17 project by the Hungarian Ministry of 
Human Capacities.
Footnote
Conflicts of Interest: The authors have no conflicts of interest 
to declare. 
References
1. Iyer MK, Niknafs YS, Malik R, et al. The landscape of 
long noncoding RNAs in the human transcriptome. Nat 
Genet 2015;47:199-208.
2. Kapusta A, Feschotte C. Volatile evolution of long 
noncoding RNA repertoires: mechanisms and biological 
implications. Trends Genet 2014;30:439-52.
3. Cheng TY, Cramb SM, Baade PD, et al. The international 
epidemiology of lung cancer: Latest trends, disparities, and 
tumor characteristics. J Thorac Oncol 2016;11:1653-71.
3640 Danis and Széll. Cellular functions of a low abundance lncRNA
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2017;9(10):3638-3640jtd.amegroups.com
4. Gutschner T, Diederichs S. The hallmarks of cancer: 
a long non-coding RNA point of view. RNA Biol 
2012;9:703-19.
5. Abba ML, Patil N, Leupold JH, et al. MicroRNAs as 
novel targets and tools in cancer therapy. Cancer Lett 
2017;387:84-94.
6. Zhang Y, Yang Q, Wang S. MicroRNAs: a new key in lung 
cancer. Cancer Chemother Pharmacol 2014;74:1105-11.
7. Castillo J, Stueve TR, Marconett CN. Intersecting 
transcriptomic profiling technologies and long non-
coding RNA function in lung adenocarcinoma: discovery, 
mechanisms, and therapeutic applications. Oncotarget 
2017. [Epub ahead of print].
8. Seiler J, Breinig M, Caudron-Herger M, et al. The 
lncRNA VELUCT strongly regulates viability of lung 
cancer cells despite its extremely low abundance. Nucleic 
Acids Res 2017;45:5458-69.
9. Ji P, Diederichs S, Wang W, et al. MALAT-1, a novel 
noncoding RNA, and thymosin beta4 predict metastasis 
and survival in early-stage non-small cell lung cancer. 
Oncogene 2003;22:8031-41.
10. Chen S, Ma P, Zhao Y, et al. Biological function and 
mechanism of MALAT-1 in renal cell carcinoma 
proliferation and apoptosis: role of the MALAT-1–Livin 
protein interaction. J Physiol Sci 2017;67:577-85.
11. Huang JL, Liu W, Tian LH, et al. Upregulation of long 
non-coding RNA MALAT-1 confers poor prognosis 
and influences cell proliferation and apoptosis in acute 
monocytic leukemia. Oncol Rep 2017;38:1353-62.
12. Jin Y, Feng SJ, Qiu S, et al. LncRNA MALAT1 promotes 
proliferation and metastasis in epithelial ovarian cancer 
via the PI3K-AKT pathway. Eur Rev Med Pharmacol Sci 
2017;21:3176-84.
13. Xu E, Yu X, Zeng Q, et al. Functional role of lncRNA 
DB327252 in lung cancer. J Thorac Dis 2016;8:2793-802.
14. Niu Y, Ma F, Huang W, et al. Long non-coding RNA 
TUG1 is involved in cell growth and chemoresistance of 
small cell lung cancer by regulating LIMK2b via EZH2. 
Mol Cancer 2017:16:5.
15. Fu X, Ravindranath L, Tran N, et al. Regulation of 
apoptosis by a prostate-specific and prostate cancer-
associated noncoding gene, PCGEM1. DNA Cell Biol 
2006;25:135-41.
16. Cai J, Wang X, Huang H, et al. Down-regulation of long 
noncoding RNA RP11-713B9.1 contributes to the cell 
viability in non-small cell lung cancer (NSCLC). Mol Med 
Rep 2017;16:3694-700.
17. Palazzo AF, Lee ES. Non-coding RNA: what is functional 
and what is junk? Front Genet 2015;6:2.
18. Kornienko AE, Dotter CP, Guenzl PM, et al. Long non-
coding RNAs display higher natural expression variation 
than protein-coding genes in healthy humans. Genome 
Biol 2016;17:14.
Cite this article as: Danis J, Széll M. VELUCT, a long non-
coding RNA with an important cellular function despite low 
abundance. J Thorac Dis 2017;9(10):3638-3640. doi:10.21037/
jtd.2017.09.66
